Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.7K

Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma

G Lorillon1, S Mourah2,3, L Vercellino4

  • 1Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, National Reference Center for Langerhans cell histiocytosis, Pulmonology Department, Paris, France.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 10, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Experiment Videos

Last Updated: Mar 16, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.

ESMO open·2026

Deciphering copper and zinc leaching from antifouling paints with different operating modes: flux determination and toxicity evidence.

Marine pollution bulletin·2026

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

European journal of cancer (Oxford, England : 1990)·2024

Outcomes of patients hospitalized in ward settings for COVID-19 pneumonia with or without early empirical antibiotics.

The Journal of antimicrobial chemotherapy·2024

First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.

ESMO open·2024

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Combined inulin, glucomannan, and medium-chain triglyceride modulate metabolic and inflammatory responses in chemotherapy-treated colorectal cancer cells.

Journal of advanced pharmaceutical technology & research·2026

Erratum: Evaluation of the combination of chitosan hydrogel crosslinker and dental pulp stem cell-derived exosomes on osteoblast viability and differentiation.

Journal of advanced pharmaceutical technology & research·2026

Engineered Nanozymes for Colorectal Cancer Therapy: Catalytic Reprogramming of the Tumor Microenvironment.

International journal of nanomedicine·2026

Selenium-Doped Calcium Hydroxide Nanoparticles Inhibit Osteoclasts and Promote Osteogenesis for Osteoporosis Treatment.

International journal of nanomedicine·2026

Efficacy of cryotherapy for oral leukoplakia: A systematic review.

Journal of dental sciences·2026

The multifaceted impact of the COVID-19 pandemic on colorectal cancer care: a systematic review of management disruptions, stage migration, and survival outcomes.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us